Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8(+) T lymphocytes that efficiently prevent tumor development. However, the therapeutic effect of such a vaccine is limited. We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8(+) T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate. As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.

Original publication

DOI

10.1007/s00262-014-1634-8

Type

Journal article

Journal

Cancer Immunol Immunother

Publication Date

03/2015

Volume

64

Pages

311 - 323

Keywords

Animals, Antigens, Neoplasm, CD8-Positive T-Lymphocytes, CTLA-4 Antigen, Cancer Vaccines, Female, Humans, Immunotherapy, Melanoma, Experimental, Membrane Proteins, Mice, Mice, Inbred C57BL, Recombinant Proteins, Trypanosoma cruzi